This company listing is no longer active
Endo International Past Earnings Performance
Past criteria checks 0/6
Key information
14.4%
Earnings growth rate
16.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -3.9% |
| Return on equity | n/a |
| Net Margin | -126.2% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Endo International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 2,552 | -3,221 | 832 | 154 |
| 30 Jun 22 | 2,783 | -2,552 | 881 | 148 |
| 31 Mar 22 | 2,928 | -681 | 870 | 147 |
| 31 Dec 21 | 2,993 | -569 | 841 | 147 |
| 30 Sep 21 | 2,964 | 129 | 767 | 147 |
| 30 Jun 21 | 2,827 | 109 | 687 | 150 |
| 31 Mar 21 | 2,801 | 137 | 688 | 151 |
| 31 Dec 20 | 2,903 | 247 | 671 | 154 |
| 30 Sep 20 | 2,908 | -102 | 661 | 125 |
| 30 Jun 20 | 3,002 | -75 | 667 | 133 |
| 31 Mar 20 | 3,014 | -190 | 648 | 129 |
| 31 Dec 19 | 2,914 | -361 | 632 | 131 |
| 30 Sep 19 | 2,936 | -418 | 639 | 122 |
| 30 Jun 19 | 2,952 | -522 | 635 | 125 |
| 31 Mar 19 | 2,967 | -477 | 630 | 181 |
| 31 Dec 18 | 2,947 | -962 | 646 | 186 |
| 30 Sep 18 | 2,929 | -968 | 640 | 209 |
| 30 Jun 18 | 2,971 | -921 | 612 | 209 |
| 31 Mar 18 | 3,132 | -1,565 | 620 | 168 |
| 31 Dec 17 | 3,469 | -1,233 | 615 | 172 |
| 30 Sep 17 | 3,942 | -4,294 | 666 | 170 |
| 30 Jun 17 | 4,039 | -4,386 | 717 | 175 |
| 31 Mar 17 | 4,084 | -3,300 | 754 | 185 |
| 31 Dec 16 | 4,010 | -3,224 | 771 | 183 |
| 30 Sep 16 | 3,842 | 553 | 802 | 181 |
| 30 Jun 16 | 3,704 | -59 | 760 | 158 |
| 31 Mar 16 | 3,518 | -539 | 721 | 126 |
Quality Earnings: ENDPQ N is currently unprofitable.
Growing Profit Margin: ENDPQ N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENDPQ N is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare ENDPQ N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENDPQ N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).
Return on Equity
High ROE: ENDPQ N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.